AmyriAD is an LA-based clinical-stage biotech company working to advance effective therapies for the treatment of Alzheimer's Disease, bringing together decades of experience with the singular goal of easing the devastation it causes. The Company's lead drug candidate, AD101, is a small molecule under development for the treatment of Alzheimer's Disease and will be entering Phase 3 clinical trials later this year in 2023 following successful randomised double-blind placebo-controlled trials where it has been administered as an add-on to stable donepezil (Aricept®) therapy.

Sharon was the global lead and development strategist for the highly successful Alzheimer’s Disease treatment, Aricept® (donepezil). From an incredible and widely varied career that started in figure skating and restaurant ownership, she has worked in high-ranking positions for several decades in the pharmaceutical industry and more recently in the startup space, leading the VC-backed AmyriAD.

We talk about one of her earliest ventures delivering food to half-naked frat boys, her expat life in Japan, and why she is so passionate about advancing a cure for Alzheimer’s Disease.

You can find out more about AmyriAD in the following ways:

Website: https://amyriadtherapeutics.com/

Twitter: https://twitter.com/AmyriAD_Tx

LinkedIn: https://www.linkedin.com/company/amyriad-therapeutics/

Find us on:

www.founders-keepers.com and www.founderskeepers.substack.com

Instagram: @founderskeepers.pod

Twitter: @founders.pod

LinkedIn: https://www.linkedin.com/company/founders-keepers-podcast

Get in touch: hi@founders-keepers.com